Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab IV vs SC Loading in RA
NCT01359943Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2011
- Primary completion
- Dec 2013
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of secukinumab in rheumatoid arthritis (RA) (3 arms), sponsored by Novartis. Primary endpoint: American College of Rheumatology 20% Response at 12 weeks. Started Oct 2011; status: completed.
02
Drugs
secukinumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01359943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01359943.